Analyst Terence Flynn from Morgan Stanley reiterated a Sell rating on Bristol-Myers Squibb (BMY – Research Report) and decreased the ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

百时美施贵宝公司(BMS)报告第三季度盈利显著增长，增长产品组合收入增加20%，现已占总收入的约一半。公司严格的费用管理和各产品组合的强劲需求是此次业绩表现的主要贡献因素。

BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics ...

Oncology, however, remains a strong suit for BMY as Opdivo continues to be a multi-billion-dollar seller and drugs like Opdualag and Krazati are showing promise in treating specific types of cancer.

The uptake of newer drugs like Opdualag, Reblozyl and Breyanzi has been strong. It is enabling Bristol-Myers to offset the loss of revenues due to declining sales of older drugs. The recent ...

At the 2024 European Society for Medial Oncology Congress, she discussed a longitudinal biomarker analysis from a phase 2 trial investigating neoadjuvant nivolumab (Opdivo) and relatlimab (Opdualag) ...